Organon benoemt Kirke Weaver tot General Counsel en Corporate Secretary
Weaver neemt officieel de rol aan nadat hij in juli 2022 interim-hoofd van het Office of General Counsel en Corporate Secretary is geworden
JERSEY CITY, N.J.–(BUSINESS WIRE)– Organon (NYSE: OGN), een wereldwijd bedrijf in de gezondheidszorg voor vrouwen, heeft vandaag aangekondigd dat Kirke Weaver is benoemd tot General Counsel en Corporate Secretary en met ingang van 1 januari 2023. De heer Weaver werd in juli 2022 aangesteld als interim-hoofd van het Office of General Counsel en Corporate Secretary.
Dit persbericht bevat multimedia. Bekijk de volledige release hier: https://www.businesswire.com/news/home/20221212005040/en/
Organon Appoints Kirke Weaver as General Counsel and Corporate Secretary
Weaver officially takes on role after becoming interim head of the Office of General Counsel and Corporate Secretary in July 2022
JERSEY CITY, N.J.–(BUSINESS WIRE)– Organon (NYSE: OGN), a global women’s healthcare company, today announced that Kirke Weaver has been appointed General Counsel and Corporate Secretary, and will continue as a member of Organon’s executive leadership team, effective January 1, 2023. Mr. Weaver was named as the interim head of the Office of General Counsel and Corporate Secretary in July 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221212005040/en/
Kirke Weaver (Photo: Business Wire)
Mr. Weaver brings nearly 20 years of pharmaceutical industry experience to the role, successfully providing legal and business advice in the multi-faceted, changing healthcare environment. Prior to serving as interim General Counsel and Corporate Secretary, Mr. Weaver served as Senior Vice President, Commercial, Regulatory, Securities, Employment and Deputy Corporate Secretary at Organon. As a senior member of the legal leadership team, he was critical to launching Organon as a standalone company in June 2021.
“Since being named as the interim head of the Office of General Counsel, Kirke has contributed deep, invaluable expertise to guide Organon, as we continue our journey to become a women’s health leader,” said Kevin Ali, CEO. “He brings excellence to the role, but also exemplifies our values by ensuring, above all else, our company’s commitment to operating with ethics and integrity.”
Prior to joining Organon, Mr. Weaver was a valuable member of the legal team at Merck, known as MSD outside the United States and Canada, most recently serving as Vice President, Office of General Counsel. He joined Merck in 2003, and held positions of increasing responsibility. He holds a B.A. from the College of William & Mary and a Juris Doctor (J.D.) degree from Yale Law School.
“I am excited to continue to lead Organon’s Office of General Counsel as we build a company to serve an important purpose in women’s health,” said Kirke Weaver. “I look forward to continuing to bring my skills to help solve critical issues that impact women and ultimately, society at large.”
Organon is a global healthcare company with a focus on improving the health of women throughout their lives. Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the women’s health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in innovation and future growth opportunities in women’s health. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.
Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 10,000 employees with headquarters located in Jersey City, New Jersey.
For more information, visit www.organon.com and connect with us on LinkedIn and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221212005040/en/